INCY vs KURA
INCY: Incyte is a biopharmaceutical company focused on discovering and developing innovative medicines for oncology and inflammatory conditions. KURA: A clinical-stage oncology biopharmaceutical company developing targeted, small-molecule precision therapies for cancer patients.
Side-by-side fundamentals
| Metric | INCY | KURA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $112.75 | $10.52 | |
| Market cap | $22.5B | $936M | |
| P/E as of 2026-10-08 | 14.37 | n/a | |
| Net margin FY2025, SEC XBRL | +25.0% | -412.9% | INCY higher |
| Operating margin FY2025, SEC XBRL | +29.5% | -449.9% | INCY higher |
| ROE FY2025, SEC XBRL | +24.9% | -160.0% | INCY higher |
| ROA FY2025, SEC XBRL | +18.5% | -37.7% | INCY higher |
| Debt / equity as of 2026-09-02 | 0.01 | 0.09 | INCY lower |
| Revenue growth (YoY) as of 2026-09-02 | +26.9% | +29.5% | KURA higher |
| Revenue CAGR (3y) SEC XBRL | +14.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.55 | 1.04 | |
| 1-year return as of 2026-10-08 close | +32.1% | +4.4% | INCY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.